Polymorphonuclear neutrophil (PMN) accumulation within damaged tissues, a hallmark of acute inflammation, is dependent upon initial adhesion to endothelial cells. In vitro studies suggest that P-selectin and platelet activating factor (PAF) are key molecules in this process by promoting the initial adhesion of PMN to endothelial cells. We report in vivo studies in which intravenous administration of lipopolysaccharide (LPS) to anesthetized rats caused a very rapid onset (<5 min) of neutropenia, in association with induction of surface expression of P-selectin on microvascular endothelial cells in kidney, liver and lung; analogous induction of P-selectin expression by cultured endothelial cells was observed in response to LPS stimulation in vitro. In addition, treatment with an antibody (Ab) to P-selectin (or use of a PAF antagonist) blocked development of neutropenia in vivo for at least 15 min post-LPS injection, and Ab treatment was shown to block PMN accumulation in tissues. These studies document roles for P-selectin and PAF in the early adhesion of PMN to endothelial cells in vivo.
I
nflammation is usually a beneficial process leading to destruction or isolation of injurious agents and tissue repair. However, in situations such as gram-negative sepsis, this response may be excessive, and cellular infiltration, endothelial damage, and vascular leakage can lead to extensive tissue injury. Accumulation of leukocytes, particularly PMN, is an important and early component of this inflammatory response (1) . A three-step mechanism for the binding of PMN to endothelial cells is proposed (2) , whereby reversible adhesion through binding to selectin molecules is followed by PMN activation and activation-dependent binding. The nature of the molecules involved in these interactions appears to depend upon the type and length of exposure of the inflammatory stimulus. P-selectin (also known as CD-62, GMP-140, or PADGEM) is normally located in r granules of platelets and the Weibel-Palade bodies of endothelial cells, but is rapidly expressed on the surface of stimulated endothelial cells (3, 4) . Surface-expressed P-selectin mediates the "rolling" of PMN, whereby the cells are slowed and brought into close vicinity of the endothelium, allowing further adhesive interactions to occur (5) . In vitro, P-selectin expression is rapidly induced by thrombin or histamine, peaks at 5-10 min after stimulation and, because of reinternalization, is largely absent by 20 rain (3, 6) , suggesting that a transient appearance in membrane P-selectin may be of significance in some of the earliest events of inflammation.
Platelet activating factor (PAF) is a potent, biologicallyactive phospholipid implicated in many inflammatory reactions, including endotoxic shock (1) and endotoxin-induced lung injury (7). Like P-selectin, PAF expression by endothelial cells is maximal within 5-10 min of stimulation and returns to background levels shortly thereafter (6, 8) . PAF contributes to PMN adhesion and activation, and PAF-primed PMNs damage endothelial cells (1, 9) . Moreover, treatment of endothelial cells with the combination of an anti-P-selectin Ab and PAF-antagonist completely blocks PMN adhesion in vitro (6) . This observation, plus the rapid and transient nature of their surface-bound expression on endothelial cells, have led to the concept that P-selectin and PAF act synergistically in promoting the early adhesion of PMN to endothelium. Specifically, rapid endothelial expression of P-selectin could mediate the initial tethering of PMN to endothelial cells, independently of CDll/CD18 ~ integrins, whereas associated endothelial PAF expression induces juxtacrine activation of surface CDll/18 molecules on PMN and their high affinity binding to endothelial-expressed ICAM molecules (2, 6, 9) . Targeting of P-selectin and PAF may thereby prove of therapeutic efficacy in blocking initial PMN adhesion to endothelium in vivo.
To this end, since LPS is present within the cell wall of gram-negative bacteria, is implicated in the pathogenesis of septic shock (10) , and is known to induce a marked neutropenia upon intravenous administration (11), we investigated the role of P-selectin and PAF in early PMN adhesion to endothelium in vivo, using a rat model of systemic endotoxemia.
Materials and Methods
Reagents and Cells. LPS and lactoperoxidase were purchased from Sigma Chemical Co. (St. Louis, MO). RPMI 1640 and FCS were obtained from Whittaker Bioproducts (Walkersville, MD), and 1~I was supplied by Amersham Radiochemicals (Amersham, UK). Thrombin was purified as described (12) . Details of a blocking, af~nity-purified rabbit anti-human P-selectin Ab and control, nonimmune rabbit IgG (13), plus a method for their pepsin digestion and purification as F(ab')2 fragments, were reported previously (14) . Anti-rat PMN mAb (RP-3) (15) was a gift of Dr. F. Sendo (Yamagata University School of Medicine, Yamagata, Japan). The synthetic PAF analogue, CV-3988 (16), was obtained from Takeda Chemical Industries (Osaka, Japan) and dissolved in 0.9% saline just before injection. HLo60 cells, obtained from American Type Culture Collection (Rockville, MD), were cultured under standard conditions, and platelets were isolated from citrated plasma (13) .
Effect of Anti-P-selectin Ab on Rat P-selectin In Vitro. The ability of anti-P-selectin Ab to block rat P-selectin was tested by study of neutralization of rat platelet rosette formation with HL-60 cells (13) . Briefly, thrombin-activated human or rat platelets (2 x 10S/ml) were preincubated with specific Ab or control Ig for 20 min before addition to HL-60 cells (2 x 106/ml); platelet rosetting was evaluated on a cell suspension by scoring a minimum of 100 cells/assay.
Induction of P-selectin on Endothelial Cells In Vitro.
Human umbilical endothelial cells were cultured in 25-cm 2 flasks (Costar Corp., Cambridge, MA) according to Jaffe et al. (17) . Actively growing, subconfluent cultures (second passage, ,~10,000 cells/ well), or in two experiments, confluent endothelial cell cultures, were washed six times in buffer (PBS/0.5% human serum albumin), stimulated with thrombin (1 U/ml) or LPS (1 #g/ml) for 10 min at room temperature, and washed six times in buffer. Surfaceradiolabeling using 12SI-lactoperoxidase, immunoprecipitation with anti-P-selectin or control Ab, and analysis by gel electrophoresis and autoradiography were performed as described by Goding (18) . Briefly, endothelial cells were iodinated, scraped, and solubilized using 0.1 M-Tris/0.1% EDTA/0.1% NP-40 (1 h, 4~ nuclei pelleted by centrifugation, and the endothelial cells lysate precleared by two incubations with nonimmune serum, followed by specific Ab, six washes, SDS-PAGE (10% gels run under reducing conditions), and autoradiography overnight at -70~
In Vivo Model of Endotoxemia. Specific-pathogen-free male
Brown Norway rats (100-200 g) were obtained from the Animal Resource Center (Willetton, WA). To assess the effects of endotoxin administration on circulating PMN, rats were anesthetized with ether and injected with LPS (5 mg/kg i.p.). The effects of P-selectin Ab were determined by intravenous injection of whole or F(ab')2-fragment of anti-P-selectin Ab or control rabbit Ig immediately before LPS administration. An Ab concentration of 2.5 mg/kg was used, based upon preliminary dose/response data. The PAF antagonist, tested at doses from 5-40 mg/kg, was injected pre-LPS, either alone or in combination with anti-P-selectin Ab. Blood samples (0.5 ml) were collected in sterile glass tubes containing 10 #M EDTA just before LPS injection, and thereafter at 5-min intervals for 20 min, to allow serial analysis of PMN levels and, as appropriate, measurement of the concentration of rabbit Ig. Data were collected from five rats/treatment group per time-point.
Quantitation of Circulating PMN. Acridine orange/ethidium bromide (0.1%) was added to aliquots of blood, to assist in recognition of leukocytes vs. RBC, and total leukocyte counts were performed using a Neubauer hemocytometer under a phase microscope equipped for fluorescent microscopy. Differential cell counts were performed on hematoxylin and eosin-stained, methanol-fixed blood smears; 500 leukocytes/smear were counted, and total PMN numbers were determined by reference to total leukocyte counts. Given variable PMN counts, results were expressed as a percentage of the PMN count for that animal pre-LPS injection. The statistical significance of data was assessed using the Instat program (GraphPad Software, San Francisco, CA); p <0.05 in the nonparametric MannWhitney U-test was considered significant.
Detection oJ Rabbit Ig by ELISA. Serial circulating levels of rabbit
Ig in Ab-injected rats were determined by ELISA, as described (14), using appropriate peroxidase-conjugated goat antibodies (The Jackson Laboratories, Bar Harbor, ME) to detect either whole or F(ab')2-Ab fragments.
Immunohistologic Studies. After rats were killed under anesthesia, lung, liver, and kidney tissues were removed from normal or LPSinjected rats (5, 10, 15, or 20 min post-injection), plus rats given rabbit Ab (anti-P-selectin or control Ig) or PAF antagonist before LPS injection. Tissues were snap-frozen in liquid nitrogen and stored at -70~ P-selectin expression and PMN infiltration were assessed in cryostat sections stained using a peroxidase-antiperoxidase method (19) . Since preliminary studies showed a close correlation between morphologic detection and RP3 mAb labeling, PMN infiltration was determined by counting RP3 + cells (20 high power fields/tissue section, 3 levels within each tissue) and comparing data between groups (n = 3/group), as described for circulating PMN.
Results and Discussion

Anti-P-selectin Ab Blocks Rat P-selectin Function In Vitra
Anti-P-selectin Ab blocked the binding of thrombin-activated human rat platelets to HL-60 cells in vitro (Fig. 1) , whereas control rabbit Ig had no effect, indicating the ability of an anti-human P-selectin Ab to block rat P-selectin, as was also reported by Mulligan et al. (20) . (data not shown). These data show that LPS, like the known agonists, histamine, and thrombin (6), can rapidly stimulate P-selectin surface expression by endothelial cells.
LPS Stimulates Surface Expression of P-selectin by
Immunoperoxidase Localization of P-selectin. Sections of lung, liver, and kidney from normal rats lacked demonstrable P-selectin, whereas surface microvascular endothelial labeling was seen within 5 rain of LPS administration (Fig. 3) . Such expression of P-selectin upon LPS stimulation must reflect transport from a preformed pool, given the rapidity of the response. LPS was recently shown to transiently induce mRNA in mouse liver, lung, kidney, and heart, with peak mRNA detected at 4 h post-stimulation (21); such mRNA induction presumably precedes synthesis and replacement of depleted cytoplasmic P-selectin stores. The lack of cytoplasmic labeling for P-selectin in unstimulated cells may reflect masking of the particular epitope(s) recognized by the Ab used, and contrasts with another Ab to P-selectin that reportedly recognizes the molecule within cytoplasmic Weibel-Palade bodies but not after its surface expression by stimulated endothelial cells (22) .
A nti-P-selectin A b Administration Blocked LPS-induced PMN Pooling in Various
Organs. RP3 + PMN were present in variable and often large numbers within sections of normal lungs of specific pathogen-free rats, which limited assessment of the extent of pooling caused by LPS administration, and the ability of an anti-P-selectin Ab to block such accumulation. By contrast, sections of normal liver or kidney from such animals essentially lacked PMN (Table 1) , allowing assessment of the effects of LPS administration. Both organs showed infiltration by large numbers of PMN by 15 rain post-LPS injection in a comparable distribution to that seen for newly expressed P-selectin (Fig. 3) , whereas P-selectin Ab, but not control Ig, caused a highly significant level of inhibition of such PMN accumulation (Table 1, Fig. 3 ).
Anti-P-selectin Ab Administration Blocked LPS-induced Neutropenia In Viva
Consistent with its effects on pooling of PMN in various tissues, intravenous LPS caused a rapid and sustained neutropenia (Fig. 4) . Within 5 rain of injection, circulating PMN levels dropped to <40% of normal and thereafter remained at 20-40% of pretreatment values. These findings suggest that the PMN were removed from the circulation by adherence to rapidly induced endothelial adhesion molecules, or simply by pooling within highly vascularized tissues in the absence of increased endothelial adhesivity, or a combination of the two.
Adherence of PMN to P-selectin in vivo was shown by the effect of injection of anti-P-selectin Ab immediately before LPS administration, which resulted in the maintenance of PMN levels at >190% of baseline for the first 15 min (Fig.  4) . Results were significantly greater than in rats receiving LPS plus control Ig (Mann-Whitney U-test, p <0.01 at 5 and 10 rain), and comparable effects were seen using an F(ab')2 fragment of the anti-P-selectin Ab (not shown). Treatment with control rabbit Ab (Fig. 4) did not significantly differ from treatment with LPS alone (Mann-Whitney U-test; p >0.2 at all time points). Regardless of anti-P-selectin Ab administration, PMN counts in LPS-injected animals progressively declined after 15-20 min. This effect was not due to clearance of whole or F(ab')2 Ab from the circulation since ELISA measurements showed persistence of rabbit Ig levels at/>5 #g/ml at all times (not shown). These data suggest that the rapid onset of neutropenia induced by LPS administration is due to adhesion of PMN to P-selectin expressed on the surface of endothelial ceils, but that P-selectin expression is not the mechanism for persistence of neutropenia beyond 15-20 rain post-LPS injection in this model. Anti-Pselectin Ab treatment had no effect on LPS-induced TNF production in vivo as assessed by assay of serum samples (not shown).
Pretreatment with a PAF Antagonist Blocked LPS-induced Neutropenia, Pretreatment of animals with the PAF antagonist (40 mg/kg) maintained PMN counts at 90-100% of normal at all time-points to 20 rain despite LPS injection (Fig. 5) . Lower doses of PAF antagonist had progressively less efficacy in blocking development of neutropenia, and by 5 mg/kg had no significant effect at all. No synergy between anti-Pselectin Ab and PAF antagonist in blocking the early effects of LPS was found, possibly due to the potency of each agent when given at the dose indicated, or the sequential rather than concomitant expression on endothelial cells of each molecule or their receptors. Detailed evaluation of multiple dosage combinations was precluded by the limited availability of the polyclonal Ab. In addition, these studies do not preclude a role for the indirect action of endotoxin via effects on complement, platelets, histamine release, PMN deformability, or other factors (23, 24) . These studies show that LPS causes a rapid and profound Development of LPS-induced neutropenia (--0-) Figure 5 . was blocked by pretreatment (--O-) with PAF antagonist (40 mg/kg); results were significant (*/, <0.05) at 5, 15, and 20 rain, and highly significant (** p <0.01) at 10 min post-LPS.
degree of neutropenia in vivo, in association with stimulation of endothelial cell surface P-selectin expression. Targeting of either P-selectin or PAF maintains circulating neutrophils levels and provides initial protection of the host against the potent effect of LPS. However, consistent with the transient expression of these molecules shown by previous in vitro studies, targeting of P-selectin or PAF does not prevent progressive development of neutropenia after 20 min. These in vivo data provide evidence for an early and transient role of P-selectin and PAF in inflammation, and experimental support for a multistep model of leukocyte adhesion to endothelium.
